Winter Capital invites university students studying in financial, economic and mathematical specialties to take part in the “Surpass Dreams” partner scholarship programme.
The programme was founded by the partners of Troika Dialog investment company. It has an educational focus, with the aim of supporting talented students, helping them to realise their professional and creative potential.
The training is free and conducted by recognised experts and financial market gurus – business owners and leaders of well-known companies. The best graduates of the Surpass Dreams programme will receive the opportunity to have an internship in partner companies, including Winter Capital.
Application is available from the programme’s website until 5 November 2018 inclusive: https://www.troikastudents.org[post_title] => Winter Capital invites applications for the Surpass Dreams scholarship programme [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => winter-capital-invites-applications-for-the-surpass-dreams-scholarship-program [to_ping] => [pinged] => [post_modified] => 2018-11-07 16:29:58 [post_modified_gmt] => 2018-11-07 13:29:58 [post_content_filtered] => [post_parent] => 35 [guid] => http://wintercapital.com/?page_id=491 [menu_order] => 0 [post_type] => page [post_mime_type] => [comment_count] => 0 )
Petrovax Pharm has launched production of Grippol® Quadrivalent, the first Russian 4-valent vaccine to prevent flu. Presently it is the most advanced full-cycle flu vaccine manufactured in Russia. The new vaccine is expected to further enhance the quality of the national healthcare system in the area of influenza prevention, and to provide a boost to Russia's pharmaceuticals exports.
Petrovax Pharm has also finished the construction of a RUB 1bn production line for drug substances and finished dosage forms. It will allow the company to increase the production of APIs by more than twofold, suppositories 4-fold, tablets 7-fold and create more than 70 new jobs. This project will spur the company’s growth in the Russian pharma market, expanding its export capacity and creating contract manufacturing expansion prospects, including import substitution opportunities.
Petrovax Pharm’s manufacturing complex has been operating under all applicable GMP and ISO guidelines for 10 years and is currently one of the most advanced high-tech biopharma facilities in Russia.[post_title] => Petrovax Pharm produces Grippol® Quadrivalent and launches 3rd production line [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => petrovax-pharm-produces-grippol-quadrivalent-and-launches-3rd-production-line [to_ping] => [pinged] => [post_modified] => 2018-11-07 16:34:19 [post_modified_gmt] => 2018-11-07 13:34:19 [post_content_filtered] => [post_parent] => 35 [guid] => http://wintercapital.com/?page_id=498 [menu_order] => 0 [post_type] => page [post_mime_type] => [comment_count] => 0 )
an investment advisory firm
focused on private equity and
venture capital in Russia and Europe